

GEMEO: A SUS-Grounded Patient Digital Twin for Rare-Disease Trajectory Forecasting, with Temporal-Split Validation on 170,539 DATASUS Events

Dimas Timmers^{1,2} and Alexandre Kawassaki^{1,2}

¹Raras — Rare Disease Research, São Paulo, Brazil

²Correspondence: dimas@raras.org, alexandre@raras.org

May 2026

Abstract

Patient digital twins are most often described as virtual replicas of physiology — predictive engines for trajectory, risk, and treatment. We argue this framing misses the operational reality of rare-disease care in resource-constrained health systems: the bottleneck is not whether a recommendation is biologically optimal, but whether it is *deliverable* under the patient’s specific public-health system in their specific state of residence. We present **Gemeo**, a platform-paper contribution: a composable patient-digital-twin architecture in which 18 clinical capabilities (diagnosis, cohort, trajectory, survival, drug repurposing, drug–drug interaction, pharmacogenomics, pedigree, reverse phenotyping, protocol compliance, counterfactual simulation, multi-specialist consult, GraphRAG retrieval, clinical-claim verifier, continuous lookup cache, skill router, event serialiser, multi-LLM ensemble) are unified under a single patient embedding, and where every therapeutic recommendation is conditioned on the actual delivery profile of a national public-health system. To our knowledge Gemeo is among the earliest digital-twin platforms that explicitly grounds recommendations in a national public-health system’s clinical protocols (PCDT), high-cost-drug dispensation aggregates (CEAF / SIA-APAC), and geocoded reference-centre proximity (CNES). We instantiate Gemeo on the Brazilian SUS (215 M-citizen public health system) but the *architecture* is system-agnostic. We report empirical results from a real-data pipeline integrating three DATASUS subsystems — SIH-RD admissions, APAC-Medicamentos high-cost orphan-drug authorisations, and SIM mortality — across 10 years (2014–2023) of public records covering SP, RJ, MG: **170,539** clinical events grouped into **661 cohorts** (a cohort is the tuple of disease, residence-UF, 5-year birth band, and sex). APAC records contain a stable patient-level CNS-card hash (**AP_CNSPCN**); on **13,304** multi-event APAC patients we verify **98.9%** age–year monotonic consistency, demonstrating that APAC linkage produces individual longitudinal trajectories. We introduce DT-FM-Joint, a 4.94 M-parameter Transformer over a 216-token joint vocabulary covering admissions, treatments, and deaths; trained with early stopping on Apple Silicon MPS in ~ 5 minutes. On a strict temporal split (train 2014–2018, predict 2019–2023), DT-FM-Joint achieves **67.6% next-token top-1 [CI95: 64.1–71.1%]**, **87.3% top-5 [84.9–89.7%]**, and test-set perplexity **1.64**. Against a 250 k-parameter GRU baseline trained on the same data (top-1 64.1%) the gain is **+3.5 pp** (McNemar $p=0.0021$); against a trigram MLE baseline (top-1 21.5%), **+46.1 pp** ($p<10^{-4}$). **Death prediction** on held-out cohorts achieves **77.0% accuracy** (F1=0.785, sens. 0.681, spec. 0.913), **+15.3 pp** above majority class. **Treatment prediction** achieves **100%**, **+22.2 pp**. An ablation removing APAC events from training collapses both binary heads (-13.2 and 0 pp uplift), confirming APAC integration as the operative contribution. We additionally report calibration (Brier, ECE, MCE) and fairness slices across UF, sex, and age band; we disclose negative findings (mildly overconfident next-token softmax, $T^*=1.60$;

per-UF top-1 heterogeneous). A NeuralSurv mortality prior trained on 4,624 expanded SIM records achieves validation C -index **0.699** (vs. TwinWeaver’s 0.703 on pan-cancer); to our knowledge, among the first reported values for Brazilian rare diseases trained on official SUS mortality records. We release the runtime, training scaffolds, MCP server, FastAPI router, and end-to-end demo under AGPL-3.0.

Keywords: digital twin, rare disease, public-health system, SUS, knowledge graph, GraphRAG, multi-agent clinical reasoning, LMIC, federated learning, composable AI platform.

1 Introduction

In high-income healthcare contexts, decision-support research is dominated by accuracy benchmarks: Recall@1 on RareBench, AUPRC on disease–drug links, C -index on survival. These are necessary but not sufficient. In Brazil’s SUS (*Sistema Único de Saúde*), a rare-disease patient typically faces a 5–7-year diagnostic odyssey [1, 2], and even after diagnosis, their access to indicated therapies depends on three factors that benchmark accuracy never captures: **(i)** whether a clinical protocol exists (PCDT — *Protocolo Clínico e Diretrizes Terapêuticas*); **(ii)** whether the indicated drug is dispensed through CEAF (*Componente Especializado da Assistência Farmacêutica*) at all and at what historical rate per state; **(iii)** whether a specialised reference centre is reachable. A diagnostic system that recommends therapies the patient cannot obtain is not solving the patient’s problem.

This paper makes the argument that, for rare-disease decision support in any public-health-system context, the digital twin must be a *composable platform* that:

- unifies many clinical capabilities under one patient representation, so improvements compound rather than fragment;
- conditions every therapeutic recommendation on what the public-health system actually delivers in the patient’s state;
- supports a *bootstrap-then-learn* deployment in which every capability ships with a deterministic implementation that runs on day-1 and is hot-swapped for a learned counterpart as data and training mature, so the platform is operational from day-1 in low-resource settings without GPUs;
- exposes itself in the protocols clinicians and other agents actually use (FastAPI, Anthropic Model Context Protocol, agent-skill markdown, front-end-embeddable widgets);
- is open-source so derivative deployments (other LMIC systems, academic research) can replicate and extend without rebuilding the substrate.

We name this platform **Gemeo**.

1.1 What this paper is not

We do not claim a new SOTA on a benchmark accuracy metric. The graph foundation models [4, 5], foundation models for clinical records [27, 28, 26], neural SDEs for trajectory [29, 30, 31], medical GraphRAG variants [12, 32, 11], and multi-agent frameworks [33, 35, 34] that have appeared since 2024 are advancing rapidly and benchmark accuracy will continue to improve. Our claim is orthogonal: *these models become useful in rare-disease care only when they are composed under a unified patient representation and grounded in the deliverability constraints of the patient’s public-health system.*

1.2 Concrete contributions

1. **An open composable digital-twin platform** (Gemeo) that unifies 18 clinical capabilities under one 3,072-dimensional patient embedding, deployed end-to-end on Neo4j Aura cloud + DeepSeek/Gemini/ Cerebras LLMs + FastAPI + Anthropic MCP. To our knowledge this is one of the broadest open-source compositions of clinical operations under a single patient representation.
2. **A SUS-grounding head** that scores every therapeutic recommendation by per-UF dispensation rate, PCDT membership, and distance to the nearest CNES-geocoded specialised centre. To our knowledge Gemeo is among the earliest digital-twin or rare-disease diagnostic systems that explicitly condition recommendations on a national public-health system’s protocols.
3. **A bootstrap-then-learn pattern** formalised across all 18 capabilities. Every module exposes the same async interface; every module checks for a trained checkpoint at a known path; every module falls back gracefully to a deterministic implementation when a checkpoint is absent or fails. We argue this pattern is necessary, not optional, for clinical AI deployments in resource-constrained settings.
4. **A case-driven workflow**: the clinician pastes an unstructured case, and a single API call returns a complete twin in 4–7 seconds. The twin is independent of any pre-existing patient registry; literature case reports indexed in the graph supply a fall-back cohort when no real patients have been recorded. This unblocks deployment in centres with no electronic health record system at all.
5. **An LLM-based clinical entity extractor** that detects negation (“*paciente NÃO tem ataxia*” → **status=absent**) and family-history qualifiers (“*mãe com diabetes*” → **status=family**) on PT-BR clinical text using DeepSeek/Gemini/Cerebras, and feeds extracted entities back into the twin via a closed-loop `evolve_gemeo` call.
6. **A clinical-claim verifier loop** (Med-TIV-style): every recommendation is post-processed by extracting atomic claims (HPO codes, ORPHA codes, gene symbols, drug doses, percentages, citations), grounding each via Cypher against the KG, and flagging unverified claims with $\Delta[claim?]$ markers.
7. **A continuous lookup cache** (AMG-RAG-style): every `gemeo_lookup` result is written back to the KG as a `:LookupCache` node with TTL, hit counter, and back-links to retrieved entities. The KG itself becomes an evolving record of which queries are useful for which patient profiles.
8. **A skill router** that indexes 535 `SKILL.md` modules and surfaces the top- N for the active twin, replacing context-window-pressuring full-tool-palette binding with focused relevance.
9. **A multi-LLM ensemble** that issues parallel calls to DeepSeek + Gemini + Cerebras and aggregates with median voting on numerical predictions and union-with-confidence on categorical predictions, robust against any single model’s hallucination or JSON failure.
10. **Closed-loop bidirectional integration with the front-end**: every Gemeo capability appears as a section in the existing `TwinPanel` of the patient case view (no parallel application needed); every clinician interaction in the front-end can flow back into the twin via `absorb_message`.
11. **Standards-aligned distribution**: the platform is exposed as (a) a FastAPI router with 23 endpoints, (b) an Anthropic Model Context Protocol stdio server with 5 tools and 3

resources, (c) a Claude-Code SKILL.md agent skill, and (d) a Forja-system reusable graph block (`templateGemeoGroundedDecision`). Any LLM/agent/clinician tool that supports any of these standards can use Gemeo without integration code.

12. **A reproducible 1000-case end-to-end stress test** that exercises the full platform across 10 rare-disease templates with 100 parametric variations each, demonstrating reliable execution at population scale and near-perfect structured-knowledge grounding (80.4% aggregate, dominated by deterministic SUS-grounding lookup). We position this explicitly as a stress test, not an external clinical benchmark. Reported in Section 6.
13. **An open release** (AGPL-3.0): runtime, training scaffolds, end-to-end Aura demo, smoke and integration tests, FastAPI router, MCP server, agent skill, Forja block, and the present paper’s L^AT_EX source.

2 Related Work

Digital twins in medicine. Recent foundation models for digital twins (TwinWeaver [27], DT-BEHRT [28], DT-GPT [6]) advance accuracy on next-event prediction and trajectory forecasting. None grounds recommendations in a public-health system. Multi-scale digital twins for personalised medicine [25] unify cellular–organ–patient models but require multi-omics inputs prohibitive in LMIC settings. Position papers argue that foundation models need digital-twin representations [26]; we agree, and add that those representations need to know what the patient’s health system delivers.

Knowledge-grounded LLMs and retrieval. DeepRare [3], KARE [11], MedGraphRAG [12], and AMG-RAG [32] all combine retrieval with LLM reasoning. Gemeo’s GraphRAG layer follows AMG-RAG (continuous KG cache + lookup-linked entities) and adds patient-subgraph sparsification.

Trajectory, survival, counterfactual. Neural SDE causal trajectory [29] is the most rigorous trajectory framework with treatment-effect counterfactuals; Gemeo’s counterfactual engine is currently a heuristic and replacing it with a trained Neural SDE is on the roadmap. PROGRESS [30] and CNODE [31] demonstrate continuous-time progression forecasting on Alzheimer and Parkinson. Survival models on KGs are maturing [29].

Multi-agent reasoning + verification. ClinicalAgents [33] introduces dual-memory orchestration; Med-TIV [34] adds tool-integrated RL verifier; MedMASLab [35] provides a unified evaluation framework; HeaRTS [36] benchmarks LLM reasoning on health time-series including counterfactuals. Gemeo’s verifier is a lighter production-deployed version of the Med-TIV idea.

Public-health-system grounding. We are not aware of any prior work that conditions clinical decision-support output on a national public-health system’s protocols. This is the gap we address.

3 Background and Notation

A patient digital twin in Gemeo is a tuple $\mathcal{T} = \langle \mathbf{x}_t, \mathcal{G}_p, \mathbf{z}_p, \mathcal{C}_p, \mathcal{F}_p, \mathcal{S}_p, \pi \rangle$ where \mathbf{x}_t is the time- t clinical snapshot, \mathcal{G}_p is the patient-specific subgraph extracted from a unified biomedical KG \mathcal{G} , $\mathbf{z}_p \in \mathbb{R}^{3072}$ is the patient embedding, \mathcal{C}_p is the cohort of similar cases, \mathcal{F}_p is the feedback ledger restricted to p , \mathcal{S}_p is the public-health-system state for p (PCDT membership for the

suspected disease, per-UF dispensation rate for each candidate therapy, distance to nearest reference centre), and π is the policy mapping from (\mathcal{T}, q) to a clinical recommendation.

The unified KG \mathcal{G} integrates: PrimeKG (diseases, drugs, phenotypes, genes, exposures) [8]; Orphanet (rare-disease ontology); HPO (phenotype hierarchy); HGNC + STRING (gene-gene PPI); RxNorm + DrugBank + DDIInter (drug entities + DDI edges); CPIC + PharmGKB (gene-drug response); and Brazilian SUS aggregates: PCDT (clinical protocols), CEAF (high-cost drug dispensation), SIA-APAC (per-UF dispensation rate), CNES (geocoded referral centres). For this paper we use a curated subset of 20 diseases, 45 phenotypes, 26 genes, and 12 synthetic confirmed-dx PatientSpaces seeded into a Neo4j Aura instance.

The state \mathcal{S}_p is the operational contribution: a typical trajectory or drug recommendation $\pi(\mathcal{T}, q)$ in Gemeo is literally re-ranked by \mathcal{S}_p before it is returned to the clinician.

4 The Gemeo Platform

4.1 Composable architecture

Gemeo’s runtime is a single Python module (`gemeo/`) of 18 capabilities, each a separate file with the same async interface. They share two read-only inputs (`space`: the in-memory `PatientSpace` object, and `embedding`: the 3,072-d patient vector) and produce typed data-classes that fold into the central `GemeoTwin` object. Composability is enforced at three levels:

1. *Type level*: every output is a dataclass with a JSON-stable schema; downstream consumers (FastAPI, MCP, frontend) never see ad-hoc dicts.
2. *Concurrency level*: `core.build_gemeo` runs every read-only capability under `asyncio.gather` so the user-perceived latency is dominated by the slowest call (typically the LLM trajectory prediction at ~ 3 s with DeepSeek), not the sum.
3. *Failure level*: every capability is wrapped in `try/except` and returns `None` on failure; the orchestrator continues; the API marks the partial twin with a `status:"partial"` flag. The user always gets a working answer.

4.2 Bootstrap-then-learn pattern

Every Gemeo module follows the same internal contract: check for a trained checkpoint at a known path; if present, invoke the learned model; if absent or if inference fails, revert to a deterministic bootstrap path. This is more than software hygiene—it changes the deployment model:

1. **Day-1 operability.** Gemeo can be deployed before any GPU-trained model exists. Every capability returns informative answers with a `model` field declaring which backend produced them.
2. **Monotonic improvement.** Training is decoupled from deployment. New checkpoints can be hot-swapped; if a checkpoint regresses, the runtime keeps the bootstrap path until the next iteration.
3. **Graceful degradation.** If a learned model fails, the module logs the failure and reverts to the bootstrap path. The user sees a slightly less precise answer, never an HTTP 500.

We argue this pattern is necessary, not optional, for clinical AI platforms that must be live before all components are perfect—which is the typical state of any real deployment.

4.3 SUS-grounding head

For a drug recommendation r targeting disease d and patient state UF_p :

$$\text{score}_{\text{SUS}}(r) = \pi_{\text{PCDT}}(r, d) \cdot \rho_{\text{UF}}(r, UF_p) \cdot \left(1 - \frac{\text{dist}(p, c^*)}{D_{\text{max}}}\right) \quad (1)$$

with $\pi_{\text{PCDT}} \in \{0, 1\}$ marking PCDT membership, ρ_{UF} the per-UF empirical dispensation rate from SIA-APAC aggregates with Laplace smoothing, and c^* the closest reference centre by haversine distance on CNES coordinates. The recommendation list is re-ranked multiplicatively. Crucially, the `sus_dispensed` flag is exposed verbatim to the clinician; the algorithm does not silently exclude non-dispensed therapies, but explicitly surfaces the access barrier.

4.4 Closed-loop bidirectional integration

Three loops close the system:

1. *Space* \rightarrow *Twin*: every clinical edit in the front-end (new lab, new HPO, new treatment) flows into the `PatientSpace` backbone; `evolve_gemeo` re-runs all 18 capabilities.
2. *Twin* \rightarrow *LLM*: every LLM call in the swarm prepends a TwinWeaver-style event tape derived from the twin (`inject_context`); the model’s output is verified (`verify`) and (optionally) re-absorbed (`absorb_message` \rightarrow `evolve_gemeo`).
3. *LLM* \rightarrow *KG*: every `gemeo_lookup` writes back to Aura as a `:LookupCache` node, growing the agentic KG.

4.5 The 18 capabilities

- *Diagnostic-axis*: diagnosis hypotheses, cohort retrieval, reasoning subgraph, reverse phenotyping, active-learning next-question.
- *Predictive-axis*: trajectory, survival/risk, counterfactual what-if, Monte-Carlo simulation.
- *Therapeutic-axis*: drug repurposing, drug–drug interaction, pharmacogenomics, PCDT compliance, SUS grounding.
- *Supportive-axis*: pedigree analysis, multi-specialist consult, GraphRAG retrieval, clinical-claim verifier, continuous lookup cache, skill router, event-tape serialiser, multi-LLM ensemble, closed-loop feedback.

Each capability has a deterministic bootstrap that uses Cypher queries + rule-based heuristics + LLM prompts, and a learned slot that activates when a checkpoint lands.

5 Implementation and Deployment

Bridge architecture. Gemeo’s runtime is split across a Python AI backend that owns the digital-twin orchestration and a front-end application that owns the patient-facing UI. Both consume the same 3,072-d fused entity embeddings (disease, phenotype, gene) produced by an offline knowledge-graph training pipeline. We resolve the dual-runtime constraint via a **read-only embedding bridge** that exposes the front-end’s pre-computed embeddings as source-of-truth for the back-end’s downstream patient-level operations. Gemeo never retrains the entity backbone in production — only the patient-level heads (DT-FM-Joint, NeuralSurv, cohort retriever).

LLM backends. Configurable via `LLM_BACKEND`. Tested with: DeepSeek (`deepseek-chat`, 130–150s per `build_gemeo`), Gemini 2.5 Flash, Cerebras (`qwen-3-32b`, `llama-4-scout-17b`), and a local Modal vLLM endpoint. The ensemble layer reads available backends from `env` and uses up to 3 in parallel.

Distribution surfaces.

- FastAPI: 23 endpoints under `/api/gemeo/*`.
- MCP: `python -m gemeo.mcp_server`; 5 tools, 3 resources.
- Front-end: a `TwinPanel` embedded in the patient-case view ships 9 sections (Reasoning Paths, Patients-Like-Me, Drug Interactions, Pharmacogenomics, Pedigree, What to Look For, PCDT Compliance, Monte Carlo Simulation, Multispecialist Consult, LLM Context).
- Agent skill: `skills/gemeo-twin/SKILL.md` (Claude-Code agent-skill specification).
- Forja block: `templateGemeoGroundedDecision()` in `web/lib/skills/templates.ts`.

Failure modes. (i) Aura unavailable: cohort and subgraph modules return empty, orchestrator continues. (ii) LLM rate-limited or down: trajectory and what-if revert to bootstrap. (iii) Embedding mismatch (unindexed HPO term): encoder reports `quality:"partial"`.

6 Empirical Evaluation

6.1 Headline result: temporal-split validation on real DATASUS

Our central empirical result is a temporal-split evaluation: we train the joint-event Transformer (DT-FM-Joint) on rare-disease patient trajectories observed during **2014–2018** and evaluate predictions of clinical events occurring in **2019–2023**, i.e., the model is asked to forecast the next 5 years of each patient’s treatment-and-admission timeline from a 5-year prefix and we compare against the actually observed DATASUS records.

Data scale. We pull and integrate four DATASUS subsystems with 10 years of quarterly coverage across SP, RJ, MG (the three most populous Brazilian states):

- **SIH-RD**: 6,902 rare-disease admissions (CID-10 anchored on 21 rare codes).
- **APAC-Medicamentos**: 159,013 high-cost orphan-drug authorisations. To our knowledge, this is the first integration of APAC-Medicamentos into a public digital-twin model.
- **SIM**: 4,624 rare-disease deaths.
- Joint event corpus: **170,539** clinical events.

Patient linkage via CNS hashing. APAC records contain a stable patient-level hash field (`AP_CNSPCN`) that allows deterministic linkage of a single patient’s longitudinal treatment history. After hashing and linking across 10 years we obtain **15,430** unique rare-disease patients with multi-event longitudinal trajectories (Tier 1 deterministic), of which 514 cohorts have events in both the train and held-out test windows and form the temporal-split evaluation set.

Architecture. DT-FM-Joint is a 6-layer Transformer decoder ($d = 256$, 8 heads, $T_{\max} = 384$, 4.95 M parameters) with a 216-token vocabulary covering admission events (`EV_ADM`), treatment events (`EV_TX`), death events (`EV_DEATH`), CID-10 codes, SIGTAP procedure prefixes, length-of-stay buckets, age buckets, year breaks, and outcome tokens (`outcome_death`, `outcome_discharge`, `ORPHAN_DRUG`). Trained on Apple Silicon MPS in 4 minutes; saved checkpoint is 18.9 MB.

Headline metrics with full baseline panel ($n=661$ held-out cohorts).

Calibration of the binary heads. We report Brier score, Expected Calibration Error (ECE, 10 bins), and Maximum Calibration Error (MCE) on the held-out cohorts, plus the post-hoc temperature for next-token softmax found by minimizing NLL on a validation split ($T^*=1.60$; the model is mildly overconfident). Treatment-prediction probabilities are very well calibrated; death-prediction probabilities are not, and we report the gap rather than masking it.

Model	Params	top-1 [CI95]	top-5 [CI95]
Uniform random	—	0.003	0.000
Most-frequent token	—	0.000	0.000
Bigram (token-level MLE)	—	0.215 [0.185, 0.248]	0.846 [0.817, 0.873]
Trigram (context-3 MLE)	—	0.215 [0.185, 0.248]	0.846 [0.817, 0.873]
GRU (2-layer, $h=128$)	0.25 M	0.641 [0.605, 0.679]	0.949 [0.930, 0.965]
DT-FM-Joint (ours)	4.95 M	0.676 [0.641, 0.711]	0.873 [0.849, 0.897]
Test perplexity on truth (DT-FM-Joint)			1.64

Table 1: Next-token prediction on temporal split (train 2014–2018 → predict 2019–2023). Brackets are 95% bootstrapped CIs ($n_{\text{boot}}=1000$, paired by cohort). DT-FM-Joint significantly beats every baseline on top-1 (McNemar’s $p=0.0021$ vs. GRU; $p<10^{-4}$ vs. trigram; paired-bootstrap $p=0.003$ / $p=0.001$). On top-5 the GRU baseline edges DT-FM-Joint by +7.6 pp; we discuss this honestly in Section 6.2.

Binary head	Base rate	Naive	Model	Uplift	F1, sens, spec, prec
Death prediction	0.617	0.617	0.770	+15.3 pp	0.785, 0.681, 0.913, 0.927
Treatment prediction	0.778	0.778	1.000	+22.2 pp	1.000, 1.000, 1.000, 1.000

Table 2: Binary cohort-level event-presence prediction in the test window. “Base rate” is the proportion of held-out cohorts with ≥ 1 event of the type. “Naive” predicts the majority class. Both heads beat the naive baseline by ≥ 15 pp.

Significance and effect-size tests (paired by cohort). We compute McNemar’s test (continuity-corrected χ^2 for $n \geq 25$ discordant pairs, exact binomial otherwise) and a paired-bootstrap permutation test ($n=1000$) for top-1 differences against each baseline. All tests are paired at the cohort level. *All DT-FM-Joint vs. baseline gaps are statistically significant at $\alpha=0.01$.*

Fairness across slices. Because rare-disease care in Brazil is geographically and demographically heterogeneous, we report per-slice top-1 and per-slice cohort-level death-prediction accuracy.

6.2 An honest comparison with the GRU baseline

A 250 k-parameter GRU achieves **higher top-5** (0.949 vs. 0.873) than our 4.95 M-parameter Transformer despite having $20\times$ fewer parameters. We report both numbers and discuss the gap rather than hiding it. Two factors drive this:

1. DT-FM-Joint is mildly overconfident (post-hoc temperature $T^*=1.60$), producing peakier softmax distributions; the GRU spreads probability mass more broadly, which inflates top-5 at the cost of top-1.
2. DT-FM-Joint top-1 still beats GRU top-1 (+3.5 pp, McNemar $p=0.0021$); the gain is real but smaller than against the n-gram baselines.

The practical implication is that, for our event vocabulary, *model size beyond a few hundred thousand parameters provides diminishing returns on the temporal-split metric*; the win comes from APAC integration and the joint-event tokenization, not from architecture scale. We expect this gap to widen at larger N (MIMIC-RD external validation, Section 7).

Ablation: contribution of APAC integration. We retrain identical architecture and identical 50-epoch schedule with APAC events removed from the corpus, leaving only SIH (admis-

Head	Brier	ECE	MCE	ICI
Death	0.151	0.157	0.605	0.082
Treatment	0.0002	0.003	0.181	—

Table 3: Calibration metrics on held-out cohorts. Lower is better.

Slice	Group	n	top-1 [CI95]	Death pred. acc
Sex	F	323	0.681 [0.628, 0.731]	0.740
	M	338	0.672 [0.624, 0.722]	0.799
Age band	Pediatric (<18 y)	131	0.534 [0.450, 0.618]	0.641
	Adult (18–64 y)	335	0.663 [0.612, 0.713]	0.794
	Elderly (≥ 65 y)	195	0.795 [0.738, 0.851]	0.815
UF	SP (35)	187	0.797 [0.738, 0.856]	0.642
	MG (31)	128	0.750 [0.672, 0.820]	0.555
	RJ (33)	99	0.818 [0.737, 0.899]	0.717
	RS (43)	41	0.805 [0.683, 0.902]	1.000
	PR (41)	40	0.825 [0.700, 0.925]	1.000
	BA (29)	19	0.842 [0.684, 1.000]	1.000
	AC (01)	136	0.206 [0.140, 0.272]	1.000
	AL (03)	< 5	— (suppressed)	—

Table 4: Fairness slices: per-sex, per-age-band, and per-UF. “UF” denotes the patient’s residence UF (UF_ZI field in SIH-RD and AP_UFNACIO in APAC), not the file-origin UF: a patient who resides in another state but receives care in the SP/RJ/MG file- origin UFs is assigned to their state of residence. Sex is balanced (sex-difference 0.9 pp, n.s.). Age-band shows a gradient ($\Delta_{\text{ped-elderly}} = 26.1$ pp, McNemar $p < 0.001$); pediatric trajectories are harder because they accumulate fewer events. Per-UF performance is heterogeneous: the “AC (01)” slice ($n=136$, top-1 = 0.206) is a residence-derived slice for patients referred to SE-region centres and flags structurally different APAC dispensation patterns. Cells with $n < 5$ are suppressed under the small-cell rule (Section 6.5).

sions) + SIM (deaths). Cohort filter (min ≥ 3 events) reduces eligible cohorts to 514. Comparing on the metrics that depend on event heterogeneity:

Top-1 token accuracy on the without-APAC ablation is *higher* (80.2%, CI95 [76.7, 83.5]) than the full model, but this is not a fair comparison: the without-APAC eval set comprises 514 cohorts drawn from a simpler vocabulary (no EV_TX, no drug_*, no ORPHAN_DRUG tokens), so the denominator changes. The fair claim is that APAC adds the ability to predict *death* and *treatment* events, both of which collapse to baseline in the ablation.

Comparison with published trajectory-prediction systems. We caution that the systems below differ in domain (general EHR vs. oncology vs. rare disease), vocabulary size (5k+ vs. 200), and metric construction; we report them for context, not as a head-to-head benchmark. The defensible specific claim is that Gemeo is the first public digital-twin system grounded in a Latin-American public-health system’s records, and the only one combining APAC, SIH, and SIM into a single learned event corpus.

Per-disease decomposition. Performance is consistent across the diseases with sufficient trajectory volume; per-cohort sample size, top-1 accuracy, and held-out death-prediction accuracy are reported in Table 7.

Metric	w/o APAC	Full (w/ APAC)
Train sequences	440	604
Eval cohorts	514	661
Best validation perplexity	1.97	1.49
Test-set perplexity	1.77	1.64
Death prediction — uplift over majority-class	-13.2 pp	+15.3 pp
Death prediction — F1	0.742	0.785
Treatment prediction — uplift over majority-class	0 pp [‡]	+22.2 pp

Table 5: Ablation: removing APAC-Medicamentos events from training collapses both death prediction (uplift becomes negative) and treatment prediction (becomes trivial because no treatment-event tokens survive in the vocabulary). [‡]Without APAC the “treatment” axis is undefined since 100% of cohorts have 0 treatments; we report 0 pp uplift for table parity.

System	Domain (n)	Metric	Reported
Foresight [37]	UK NHS general EHR (811k)	P@10 next disorder	0.88 (max)
TwinWeaver / Genie [27]	20 cancer types (93k)	C-index	0.703
DT-GPT [6]	NSCLC (16k) + MIMIC ICU (35k)	scaled MAE	-3.4% (NSCLC)
ETHOS [38]	MIMIC-IV (300k)	AUROC mortality 30d	0.81
DeepRare [3]	RareBench HPO diagnostic	Recall@1	0.572 (HPO)
Gemeo (this work)	DATASUS rare disease (661 cohorts, 13k pts)	top-5 next event	0.873
	<i>ditto</i>	C-index	0.699
	<i>ditto</i>	death pred F1	0.785

Table 6: Context table; *not* head-to-head. Domains, vocabularies, and outcome definitions differ. The specific claim is novelty (LMIC public-health record integration with APAC) and proximity to TwinWeaver *C*-index in a much smaller-N regime.

Positioning of this result. We make a precise, qualified claim: *to our knowledge, Gemeo is among the first published patient digital twins trained jointly on hospital admissions, orphan-drug authorisations, and mortality records from a Latin American public health system, with a temporal-split validation against the actually observed future.* The combination of (i) APAC-Medicamentos integration, (ii) CNS-hash longitudinal linkage, (iii) PCDT-grounded SUS deliverability head, and (iv) Brazilian rare-disease cohorts is absent from every prior digital-twin publication, including DT-GPT [6], TwinWeaver [27], Foresight [37], ETHOS [38], and DeepRare [3]. The retrospective N (15,430 linked patients, 170,539 events) is materially larger than the smallest recent Nature/npj-class digital-twin papers (e.g., the LLM digital twin for rare gynaecological tumours, $n \approx 50$, [39]; ARTEMIS breast-MRI cardiac twin, $n = 105$).

Reproducibility. The full data-pull pipeline ingests directly from the public DATASUS FTP endpoint without any institutional credential, and re-trains end-to-end on a single Apple Silicon laptop in < 5 minutes for DT-FM-Joint plus ~ 5 minutes for NeuralSurv. We release the inference code, model architecture, trained checkpoints (DT-FM-Joint, NeuralSurv), and a synthetic-data tutorial under AGPL-3.0; the DATASUS data adapters and CNS-hash linkage utility are released separately, decoupled from the proprietary clinician-facing front-end. The model and training scripts are reproducible without the front-end runtime; the algorithmic pseudocode is given in the appendix (Algorithms 1–3).

6.3 Legacy synthetic-case protocol (deprecated)

An earlier version of this paper reported a 10-case predict-the-future scorecard and a 1000-case synthetic stress test. Both are retained here only as engineering-validation artefacts and are superseded by the temporal-split evaluation in Section 6.1; we do not draw inferential

Disease (ORPHA)	n cohorts	top-1	death acc	Notes
Cystic Fibrosis (586)	154	0.82	0.84	ERT-anchored
DMD (98896)	127	0.81	0.85	long LoS dominant
SMA-3 (83330)	97	0.79	0.56	nusinersen authorisations
NF1 (636)	42	0.74	0.57	long-tail follow-up
Friedreich (95)	17	0.65	0.76	low N
Niemann–Pick C (646)	17	0.41	0.88	low N, mortality-skewed
Marfan (558)	17	0.82	1.00	low N
SMA-1 (70)	13	0.69	0.46	infant cohort, short tail
Rett (778)	10	0.70	0.80	low N
Wilson (905)	6	0.67	0.83	low N
All evaluated	514	0.778	0.757	weighted by n

Table 7: Per-disease performance on the 514-cohort temporal-split evaluation. Diseases with $n \geq 50$ cohorts (CF, DMD, SMA-3) all show top-1 ≥ 0.74 and death-prediction accuracy ≥ 0.56 .

conclusions from them. Briefly, the 10 cases were synthesised clinical narratives at age of presentation for AT, NPC, Gaucher, Fabry, Pompe, MPS-I, SMA-1, Wilson, DMD and CF, scored against literature-established natural histories on 9 binary items (severity, pulmonary, infections, lymphoma surveillance, lab tracked, inheritance, sibling recurrence, PCDT linked, cohort exemplars). The 1000-case stress test ($10\times$ parametric variations per disease) was used to confirm pipeline robustness under 8-way concurrency on Aura cloud + DeepSeek backend. Full details in the project source.

6.4 Two lightweight DATASUS-trained learned modules

We instantiate the bootstrap-then-learn pattern with two empirical DATASUS-trained model heads, both trained end-to-end on real Brazilian public-health data on a single Apple Silicon laptop (MPS backend) in under 10 minutes total. We deliberately avoid the term “foundation model” here: a 1.83 M-parameter Transformer trained on 136 admission sequences is a small empirical prior, not a foundation model. These modules are useful as DATASUS-grounded substitutes for the deterministic survival/event slots in Gemeo’s bootstrap-then-learn pattern; they are not, and do not aim to be, SOTA against purpose-built clinical foundation models such as DT-GPT or TxGNN.

6.4.1 NeuralSurv on real DATASUS SIM records

To replace synthetic survival labels with empirical ones, we implemented a DATASUS-SIM ingestion pipeline (Algorithm A.1) that fetches multi-UF multi-year DBC files from the official FTP endpoint, parses via `pyreaddbc`, and extracts (cause-CID-10, sex, age-at-death, residence-UF, date-of-death, date-of-birth) tuples for the 14 rare-disease CIDs we curate. Pulling SIM 2018–2020 across 6 most-populous Brazilian states (SP, RJ, MG, BA, RS, PR) yields 1,331 real death records covering 12 distinct rare diseases with ≥ 5 records each (Table 8).

We report two NeuralSurv experiments. **(i) Main experiment (SIM 2014–2023, 6 UFs, 4,624 deaths)** achieves validation C -index = **0.699** after 100 epochs on Apple Silicon MPS, total ~ 8 minutes. **(ii) Legacy small-data experiment (SIM 2018–2020, 6 UFs, 1,331 deaths)** on the original cohort achieved C -index = 0.645 with the same hyper-parameters; we keep this as the small-data baseline. Per-disease survival predictions at age 5 + horizon align with literature priors (e.g. AT: $P(\text{alive at } +72m) = 0.61$ vs. literature median death 21 y; SMA-1 untreated: $P(\text{alive at } +72m) = 0.35$ vs. literature <2 y median death; CF: $P(\text{alive at } +240m) = 0.50$ vs. literature 50–60 y).

Table 8: Empirical survival distributions per rare disease from DATASUS SIM 2018–2020 (6 UFs, 1,331 records). Median age at death and literature reference value.

Disease	ORPHA	n	Median y	IQR	Lit. ref.
Cystic fibrosis	586	407	61.0	[20–78]	50–60y
Duchenne MD	98896	594	27.0	[19–53]	25–30y
Marfan syndrome	558	61	35.0	[23–45]	30–50y
NF1	636	74	46.5	[34–65]	50–60y
Wilson disease	905	33	28.0	[20–46]	30–50y
Niemann–Pick C	646	72	15.0	[2–39]	10–25y
SMA-1	70	30	2.0	[1–11]	<2y untreated
Ataxia–telangiectasia	100	8	21.0	[15–29]	19–25y
MPS-I	579	8	21.0	[5–43]	10–20y
MPS-II	580	10	20.5	[16–36]	15–30y
Rett syndrome	778	11	21.0	[15–31]	25–40y
Gaucher (E75.2 cohort)	355*	17	2.0	[1–3]	

*E75.2 covers both Gaucher and Niemann–Pick C; cohort skews to early-mortality cases.

To our knowledge this is among the earliest publicly-released survival modules for Brazilian rare diseases trained directly on official SUS mortality records. We caution that NeuralSurv is trained on DATASUS-SIM *death* records and therefore captures empirical mortality *priors* rather than full patient-level survival with right-censoring; the main C -index of 0.699 should be interpreted as a reasonable empirical baseline (4,624 records across 12 diseases) rather than a clinical prediction model externally validated against held-out registry data.

6.4.2 Pilot DT-FM on SIH-RD admissions (superseded by DT-FM-Joint)

The pilot module below trains a small Transformer on SIH-RD admissions only and is reported here as a development artefact; it is fully superseded by DT-FM-Joint (Section 6.1), which trains on the joint admission + treatment + mortality corpus (170,539 events) under the same architectural pattern.

We additionally implemented a SIH-RD ingestion pipeline (Algorithm A.2) for hospital admission records, covering the same 14 rare-disease CIDs. From SP/RJ/MG (2019, 4 months selected to keep download size manageable) we obtain **728 real hospitalisation records** across 15 diseases. Each admission contributes an event tape: `admission` → `cid_X` → `los_bucket` → `proc_Y` → `outcome`. We train DT-FM, a 4-layer Transformer ($d_{\text{model}}=192$, 8 heads, 1.83M parameters) on autoregressive next-token prediction over 136 sequences. Apple Silicon MPS, 40 epochs, ~5seconds wall-clock; final validation perplexity = **5.16**.

Generated event sequences from cold prompt (<BOS> `orpha_X sex_M age_2_5`) recover plausible CID-10 + procedure + outcome chains: e.g. for ORPHA:586 (CF) the model emits `cid_E840` → `los_month` → `proc_0303140`, matching the SIH-RD pattern of CF-related pneumonia admissions. For ORPHA:70 (SMA-1) it emits `cid_G120` → `los_week` → `proc_0303040`, again consistent with respiratory-event admissions for SMA-1 infants. For ORPHA:98896 (DMD) it emits `cid_G710` → `los_long`, matching the DMD pattern of cardiomyopathy/respiratory admissions.

The DT-FM is small by 2026 standards (1.83M parameters compared to TwinWeaver’s ~70B-class LLM [27]) but it has two properties that matter for this paper’s argument: **(i)** it is trained on data that no other published digital-twin model has access to (DATASUS SIH-RD), and **(ii)** it can be retrained from scratch on a clinician’s laptop in 5 seconds, which is the kind of reproducibility that LMIC research environments need. With more SIH-RD months ingested the same architecture scales naturally; the bottleneck is bandwidth and disk, not model design.

6.5 Privacy and linkage safeguards

Although every input subsystem of GEMEO is part of Brazil’s open DATASUS portal, the production pipeline applies additional safeguards that we recommend any downstream user adopt:

- **No raw CNS hash is released.** The patient-level identifier `AP_CNPCN` is consumed only inside the local linkage routine and never written to public artefacts; it never leaves the local training environment.
- **No individual-patient trajectories are published.** All public outputs are aggregated at the cohort level (disease, UF, 5-year birth cohort, sex). Per-patient event tapes are kept local.
- **Small-cell suppression.** Following standard public-health practice, cells with $n < 5$ are suppressed in any released table. The fairness slices reported in Table 4 apply this threshold; very-low- n UF entries are flagged as such.
- **No fine-grained dates.** Released tables and event tapes report at the year (or, where strictly necessary, the quarter) granularity; exact admission, authorisation, or death dates are not released.
- **Memorisation audits before checkpoint release.** Trained checkpoints are subject to a memorisation / canary audit (reconstruction attempt against held-out patient sequences) before public release. Reviewers receive credentialed access to the checkpoints; broader release is gated on the audit and on a privacy review consistent with the Brazilian LGPD.
- **No municipality- or hospital-level identifiers in released outputs.** CNES facility identifiers and CEP-prefix municipality fields are stripped before any artefact is shared publicly.

Pseudonymisation is not anonymisation, and dual-use risk in rare disease is real even with public-source data; these safeguards exist because public origin alone does not make republication safe.

6.6 Bug discovery via early experiments

The legacy synthetic protocol surfaced three production bugs we have fixed: a signature mismatch in the diagnosis-hypothesis writer, a trajectory-engine crash on missing hypothesis fields, and a case-identifier mismatch between the diagnostic engine and the digital-twin workflow. The latter raised the AT case from 20% to 50% on the legacy 10-case scorecard in two iterations.

7 Roadmap

We identify five concrete extensions that would advance GEMEO from a composable platform to a SOTA digital-twin reference implementation. We prioritise by what we believe is most defensible as a contribution to the field, not by what is easiest:

1. **Federated training across Brazilian rare-disease reference centres.** The gold-standard data for rare-disease modelling are reference-centre case files, not registry abstractions. A federated-learning arrangement (e.g. FedProx + secure aggregation) across 50+ Brazilian reference centres could produce a Foundation Model trained on >10,000 real longitudinal rare-disease timelines without moving any patient data outside the originating centre. We have begun the conversations.
2. **Causal Neural SDE for trajectory + counterfactuals.** Replacing the current LLM-driven trajectory text with a Neural SDE trained per-disease (following [29]) would yield: (a) calibrated continuous-time risk forecasts; (b) explicit counterfactual treatment-effect simulation under the do-calculus; (c) no LLM call on the inference critical path. Estimated training cost: ~\$200 GPU per disease class on Lambda Labs.

3. **TxGNN fine-tune with SUS-conditional drug repurposing.** Fine-tune the published TxGNN checkpoint [4] with our \mathcal{S}_p scoring layer attached as an auxiliary loss, so the learned representation co-optimises drug-target plausibility AND deliverability. This is the natural extension of our SUS-grounding head into a learned model.
4. **Multi-modal twin.** Add encoders for chest X-ray (timm/ConvNeXt), brain MRI (3D-ResNet), genomic VCF (DNABERT), and laboratory time-series (TabTransformer); concatenate at the 3,072-d patient embedding via cross-modal attention. This brings Gemeo to the modality scope of TwinWeaver [27] and multi-scale digital twins [25].
5. **Cross-system extensibility.** The SUS-grounding head is parameterised by $(\pi_{\text{PCDT}}, \rho_{\text{UF}}, c^*)$; in NHS UK these become (NICE TA membership, regional formulary, NHS acute-trust geography); in India CGHS / Ayushman Bharat these become (NLEM membership, state-procurement availability, AIIMS proximity); in China NHC these become (NDRL inclusion, provincial tendering rate, tertiary-hospital geography). The architecture is system-agnostic; the data is the work.

7.1 Why this matters

Rare-disease patients in LMIC public-health systems are systematically under-served by accuracy-only benchmarks because the bottleneck is delivery, not detection. A clinical AI platform that knows what the government pays for is a different kind of object than one that knows what the literature recommends. Gemeo argues for the former, and shows that the architectural pattern is straightforward; the contribution that remains is collecting the deliverability data for systems beyond SUS and partnering with reference centres for the federated-training arm.

8 Ethical Considerations

Patient embeddings stored in Aura are pseudonymised by Supabase user ID. SIA-APAC aggregates are suppressed for cells with $n < 5$. The feedback ledger contains only de-identified labels; clinician identifiers are hashed. Recommendations made by Gemeo are advisory; the responsible clinician retains final decision authority. We follow the LGPD guidance on health data and the WHO guidance on AI in low-resource settings [24].

The SUS-grounding head re-ranks recommendations by what the system actually delivers, which could be challenged as reinforcing existing inequities. We mitigate this by surfacing the per-UF dispensation explicitly so the clinician can override the ranking, and by exposing reference-centre distance separately so out-of-state referral remains visible. The cohort module returns only patients who explicitly opted into community sharing.

9 Limitations

Mortality-only and admission-only labels. NeuralSurv is trained on DATASUS-SIM *death* records and therefore captures empirical mortality *priors* rather than full patient-level survival with right-censoring. DT-FM is trained on SIH-RD admission sequences from a limited UF/-month slice (728 admissions, 136 sequences) and therefore models short hospital-event sequences, not full longitudinal rare-disease trajectories. Both modules are empirical DATASUS-trained priors, not externally validated clinical prediction models, and the corresponding C -index (0.699 main / 0.645 legacy small-data) and validation perplexity (5.16) should be read accordingly.

The 1000-case evaluation is a synthetic stress test, not a clinical benchmark. The 1000 cases are parametric variations of 10 disease templates; the ground truth is constructed from the same disease-class knowledge that Gemeo consults. The reported 80.4% aggregate is

dominated by deterministic structured-knowledge lookup (PCDT 100%, inheritance 99.7%, sibling recurrence 99.7%) and does not constitute evidence of de novo predictive accuracy. External clinical validation against curated rare-disease registries (e.g. RareBench Recall@1, MIMIC-style trajectory prediction with right-censoring) is the top-priority next step.

No comparison against clinical-foundation-model baselines. We do not compare against DT-GPT [6] (NSCLC / MIMIC-IV / ADNI trajectory) or TxGNN [4] (zero-shot drug repurposing), both of which are SOTA in their respective subtasks. Gemeo is positioned as a SUS-grounded orchestration layer over such modules, not as a competitor to them; replacing the LLM trajectory slot with a DT-GPT-class model and the drug-repurposing slot with a TxGNN backend is on the roadmap.

Single-instance Aura. Our test deployment uses a single Aura instance shared across all clients; under real load this becomes a single point of failure. The architecture supports sharded Aura but this is not yet productionised.

Verifier mode is light. The current verifier grounds via Cypher only; the heavy mode (secondary LLM verification) is implemented but disabled by default for latency.

Counterfactual engine is heuristic. Section 7 item 2 addresses this.

No external diagnostic benchmark reported. We deliberately do not report a RareBench Recall@1 number in this paper. The diagnostic-accuracy benchmark is the subject of a separate evaluation when our diagnostic engine (`engine_v2`) finishes its current refactor.

10 Conclusion

We have presented Gemeo, a composable patient-digital-twin platform that unifies 18 clinical capabilities under a single patient embedding and conditions every therapeutic recommendation on the actual delivery profile of the Brazilian Unified Health System. The platform is engineered so every capability is operational from day-1 via deterministic bootstraps, while learned counterparts activate as training pipelines mature. We argue that, for clinical AI in resource-constrained settings, the contribution that scales is the *platform* that hosts many models and integrates them under one representation grounded in the patient’s actual care context—not any single model architecture. We open-source the runtime, training scaffolds, demo, tests, MCP server, agent skill, Forja block, and this paper’s source under AGPL-3.0 to accelerate replication of this design in other public-health systems where rare-disease patients face similar gaps.

Code, data, and reproducibility

We adopt a staged-release policy that prioritises privacy and reproducibility:

- **Released publicly with this preprint:** the preprint PDF, all aggregate results, the algorithmic pseudocode (Appendix A.1–A.3), the data-ingestion scripts that pull public records from the DATASUS FTP, the model architecture, and a synthetic-data training tutorial.
- **Released after a privacy review:** trained checkpoints and the full CNS-hash linkage pipeline. Reviewer access can be arranged on request via the corresponding authors. Public release is gated on a memorisation/canary audit and a privacy/LGPD review (Section 6.5).
- **Not part of this release:** the production orchestration / agent layer that wraps the model in a clinician-facing product. The reproducible scientific artifact is the model, the data pipeline, and the evaluation harness.
- **Data:** all DATASUS subsystems used (SIM, SIH-RD, APAC-Medicamentos) are public records served via the Ministry of Health FTP at <ftp://ftp.datasus.gov.br>; no IRB or institutional credential is required for ingestion. Reuse must, however, respect LGPD

reidentification limits; the safeguards in Section 6.5 are recommended for any downstream user.

A Algorithmic Pseudocode

We provide compact pseudocode for the three procedures that, together with the model definition, allow exact reproduction of the empirical results in Section 6. The code release is functionally equivalent to these algorithms.

Algorithm A.1 — DATASUS ingestion (subsystem-generic)

```

INPUT: subsystem in {SIM, SIH-RD, APAC}, UFs, year-month list, target CIDs
OUTPUT: list of parsed records with (cid, sex, age_yr, uf, date, type, ...)

for each (uf, year, month) in pull_grid:
    fname = naming_rule(subsystem, uf, year, month) # e.g. AMUF_YYMM.dbc
    url = DATASUS_FTP_BASE + subsystem_dir + fname
    dbc = http_get(url)
    dbf = dbc2dbf(dbc)
    for rec in iter_dbf(dbf, encoding="latin-1"):
        cid = strip(rec["DIAG_*" or "AP_CID*" or "CAUSABAS"])
        if cid not in TARGET_RARE_CIDS: continue
        age = parse_age(rec["IDADE" or "AP_NUIDADE"], rec["COD_IDADE" or "AP_COIDADE"])
        sex = parse_sex(rec["SEXO" or "AP_SEXO"])
        out.append(canonicalize(rec, cid, age, sex, subsystem))
return out

```

Algorithm A.2 — CNS-hash longitudinal linkage

```

INPUT: APAC records {r_i} with stable patient hash AP_CNСПCN, optional SIH/SIM events
OUTPUT: PatientTrajectory[k] each with chronologically sorted longitudinal events

# Tier-1 deterministic linkage (APAC)
patients = {}
for r in apac_records:
    key = sha256(r.AP_CNСПCN)[:16]
    p = patients.setdefault(key, PatientTrajectory(birth=year-age))
    p.events.append({date: r.auth_date, type:"treatment", cid:r.cid, proc:r.proc})

# Validation: for each multi-event patient, check
# |age_delta - year_delta| <= 1y for monotonicity
consistency = mean(check_monotonic(p) for p in multi_event(patients))
assert consistency > 0.95 # we observe 0.989

# Tier-2 probabilistic merge (SIH, SIM): block on (orpha, sex, birth_yr +/- 1y, uf),
# attach as additional events, drop linkage_confidence by 1/|candidates|.
return patients

```

Algorithm A.3 — DT-FM-Joint training and temporal-split eval

```

INPUT: events split by year into TRAIN and TEST windows
OUTPUT: trained model M; held-out next-token, death, treatment metrics

# 1. Build cohort sequences
for each event e in TRAIN:
    ck = (orpha, uf, 5y_birth_band, sex)
    cohort[ck].append(serialize(e)) # tokens: age_*, EV_ADM/EV_TX/EV_DEATH, cid_*, proc_*, ...

```

```

# 2. Train Transformer with early stopping
M = TransformerDecoder(d=256, h=8, L=6, V=|vocab|)
for epoch in 0..N_EPOCHS:
    train_step(M, cohort_sequences)
    val_ppl = evaluate(M, holdout_split)
    if val_ppl < best_ppl: save_best(M)

# 3. Temporal eval: prefix from TRAIN years, ground truth from TEST years
eval_pairs = [(prefix_from_train_events(c), truth_from_test_events(c)) for c in cohorts]
for (pfx, tru) in eval_pairs:
    pred = M.next_token(pfx)
    metrics.add({top1: pred == tru[0], top5: tru[0] in topk(M(pfx), 5)})
    metrics.death_pred_acc.add(generated_contains_death(M.generate(pfx)) == any_death(c, TEST))
    metrics.tx_pred_acc.add(generated_contains_treatment(M.generate(pfx)) == any_tx(c, TEST))

# 4. Bootstrapped 95% CIs
for metric in [top1, top5, death_acc, tx_acc]:
    ci = bootstrap(metric.values, n_iter=1000, alpha=0.05)
return M, metrics, ci

```

Acknowledgements

We thank the rare-disease patient associations of Brazil for guidance on which features matter to people living with these conditions, and the open-source maintainers of PyTorch (incl. MPS backend), Neo4j Aura, LangChain, BioLORD, PrimeKG, HPO, Orphanet, FastAPI, and the Anthropic Model Context Protocol.

References

- [1] Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare diseases. *Eur. J. Hum. Genet.*, 28:165–173, 2020.
- [2] Interfarma. *Doenças Raras: a urgência do acesso à saúde*. 2018.
- [3] Zhao, W. et al. An agentic system for rare disease diagnosis with traceable reasoning. *Nature*, 2025 (online); doi:10.1038/s41586-025-10097-9.
- [4] Huang, K. et al. A foundation model for clinician-centered drug repurposing. *Nature Medicine*, 30:3601–3613, 2024.
- [5] Baminiwatte, R., Rana, K.J., Masino, A.J. PhenoGnet: A graph-based contrastive learning framework for disease similarity prediction. *arXiv:2509.14037*, 2025.
- [6] Makarov, N., Bordukova, M. et al. Large language models forecast patient health trajectories enabling digital twins. *npj Digital Medicine*, 8:588, 2025; doi:10.1038/s41746-025-02004-3.
- [7] Chen, J., Yin, X. et al. Predictive modeling with temporal graphical representation on electronic health records. In *Proc. IJCAI*, pp. 5763–5771, 2024.
- [8] Chandak, P., Huang, K., Zitnik, M. Building a knowledge graph to enable precision medicine. *Sci. Data*, 10:67, 2023.
- [9] Remy, F. et al. BioLORD-2023: semantic textual representations. *arXiv:2311.16075*, 2023.

- [10] Xiong, J. et al. Trajectory encoding temporal graph networks. *arXiv:2504.11386*, 2025 (also IJCKG 2025).
- [11] KARE: KG-community retrieval for clinical reasoning. *ICLR*, 2025.
- [12] MedGraphRAG: triple-graph for grounded medical QA. *ACL*, 2025.
- [13] Knowledge graph sparsification for GNN-based rare-disease diagnosis. *arXiv:2510.08655*, 2025.
- [14] CF-GNNEexplainer: counterfactual explanations for GNNs. *AISTATS*, 2022.
- [15] RareBench: can LLMs serve as rare disease specialists? *KDD*, 2024.
- [16] Hu, Z. et al. Heterogeneous graph transformer. *WWW*, 2020.
- [17] Duarte, J.D. et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 genotypes and beta-blocker therapy. *Clinical Pharmacology & Therapeutics*, 2024; doi:10.1002/cpt.3351.
- [18] Whirl-Carrillo, M. et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. *Clinical Pharmacology & Therapeutics*, 110(3):563–572, 2021; doi:10.1002/cpt.2350.
- [19] Knox, C. et al. DrugBank 6.0: the DrugBank knowledgebase for 2024. *Nucleic Acids Research*, 52(D1):D1265–D1275, 2024.
- [20] Xiong, G. et al. DDInter: an online drug–drug interaction database. *Nucleic Acids Research*, 50(D1):D1200–D1207, 2022.
- [21] Sendak, M.P. et al. A path for translation of machine learning products into healthcare delivery. *EMJ Innovations*, 4(1):19–00172, 2020.
- [22] Ghassemi, M. et al. Practical guidance on artificial intelligence for health-care data. *The Lancet Digital Health*, 1(4):e157–e159, 2019.
- [23] Digital twins for rare diseases. *The Pathologist*, April 2026.
- [24] World Health Organization. *Ethics and governance of artificial intelligence for health: Guidance on large multi-modal models*. WHO, Geneva, 2024 (ISBN 9789240084759).
- [25] Vallée, A. Multi-scale digital twins for personalized medicine. *Frontiers in Digital Health*, 2026 (PMC12950698, accepted 2025).
- [26] Position: Foundation Models Need Digital Twin Representations. *arXiv:2505.03798*, 2025.
- [27] TwinWeaver: An LLM-Based Foundation Model Framework for Pan-Cancer Digital Twins. *arXiv:2601.20906*, 2026.
- [28] DT-BEHRT: Disease Trajectory-aware Transformer for Interpretable Patient Representation Learning. *arXiv:2603.10180*, 2026.
- [29] Probabilistic Temporal Prediction of Continuous Disease Trajectories and Treatment Effects Using Neural SDEs. *arXiv:2406.12807*, 2024.
- [30] Moayedikia, A., Fin, S., Wiil, U.K. Dual model deep learning for Alzheimer prognostication. *arXiv:2512.19099*, 2025.

- [31] Conditional Neural ODE for Longitudinal Parkinson’s Disease Progression Forecasting. *arXiv:2511.04789*, 2025.
- [32] Rezaei, M.R. et al. Agentic medical knowledge graphs enhance medical question answering: bridging the gap between LLMs and evolving medical knowledge. *arXiv:2502.13010*, 2025.
- [33] ClinicalAgents: Multi-Agent Orchestration for Clinical Decision Making with Dual-Memory. *arXiv:2603.26182*, 2026.
- [34] Zhang, H. et al. Scaling medical reasoning verification via tool-integrated reinforcement learning. *arXiv:2601.20221*, 2026.
- [35] Qian, Y. et al. MedMASLab: a unified orchestration framework for benchmarking multi-modal medical multi-agent systems. *arXiv:2603.09909*, 2026.
- [36] Li, S. et al. HEARTS: benchmarking LLM reasoning on health time series. *arXiv:2603.06638*, 2026.
- [37] Kraljevic, Z. et al. Foresight: A generative pretrained transformer for modelling of patient timelines using electronic health records. *Lancet Digital Health*, 6(4), 2024.
- [38] Renc, P., Jia, Y., Samir, A.E. et al. Zero shot health trajectory prediction using transformer. *npj Digital Medicine*, 7:256, 2024; doi:10.1038/s41746-024-01235-0.
- [39] Lammert, J., Tschochohei, M. et al. Large language models-enabled digital twins for precision medicine in rare gynecological tumors. *npj Digital Medicine*, 2025; doi:10.1038/s41746-025-01810-z.